Topic: dietary supplements
For years, Amarin promised that its fish-oil drug Vascepa could evolve into a blockbuster. Now, analysts are finally seeing major sales on the horizon.
Aiming to protect Vascepa's CV advantage—and its fast-growing prescription count—Amarin's fighting supplement makers in court.
@FiercePharma: ICYMI: Can J&J's Invokana reap the benefits of Lilly and BI's new cardiac data? Its CFO thinks so. Article | Follow @FiercePharma @EricPFierce: Pests, lack of data...